X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (34906) 34906
Newspaper Article (496) 496
Book Chapter (290) 290
Magazine Article (241) 241
Book / eBook (124) 124
Dissertation (115) 115
Book Review (35) 35
Reference (30) 30
Publication (25) 25
Government Document (18) 18
Trade Publication Article (17) 17
Web Resource (17) 17
Newsletter (9) 9
Report (8) 8
Streaming Video (8) 8
Journal / eJournal (3) 3
Manuscript (3) 3
Art (2) 2
Paper (2) 2
Conference Proceeding (1) 1
Microfilm (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
castration (28710) 28710
animals (19675) 19675
male (19251) 19251
female (15005) 15005
humans (12472) 12472
rats (10384) 10384
prostate cancer (4867) 4867
estradiol - pharmacology (4247) 4247
testosterone - pharmacology (3459) 3459
mice (3217) 3217
pregnancy (3112) 3112
middle aged (3095) 3095
oncology (3056) 3056
time factors (2577) 2577
aged (2568) 2568
orchiectomy (2460) 2460
adult (2251) 2251
progesterone - pharmacology (2243) 2243
testosterone (2167) 2167
urology & nephrology (1974) 1974
cancer (1912) 1912
prostatic neoplasms, castration-resistant - drug therapy (1910) 1910
prostate (1890) 1890
androgens (1818) 1818
luteinizing hormone - blood (1814) 1814
endocrinology & metabolism (1802) 1802
metastasis (1744) 1744
rats, inbred strains (1726) 1726
ovary - physiology (1706) 1706
research (1638) 1638
prostatic neoplasms, castration-resistant - pathology (1623) 1623
sex factors (1463) 1463
chemotherapy (1420) 1420
prostatic neoplasms - drug therapy (1387) 1387
adrenalectomy (1350) 1350
veterinary sciences (1328) 1328
castration-resistant prostate cancer (1325) 1325
organ size (1322) 1322
neoplasm metastasis (1309) 1309
prostatic neoplasms - pathology (1308) 1308
androgen receptor (1227) 1227
docetaxel (1202) 1202
estrus (1179) 1179
survival (1174) 1174
expression (1159) 1159
testosterone - blood (1159) 1159
care and treatment (1087) 1087
metastases (1085) 1085
age factors (1079) 1079
cell line, tumor (1071) 1071
treatment outcome (1063) 1063
analysis (1061) 1061
prognosis (1053) 1053
men (1035) 1035
antineoplastic agents - therapeutic use (1027) 1027
testis - physiology (987) 987
enzalutamide (985) 985
aged, 80 and over (979) 979
follicle stimulating hormone - blood (976) 976
receptors, androgen - metabolism (974) 974
hypophysectomy (958) 958
body weight (922) 922
sexual behavior, animal - drug effects (912) 912
therapy (896) 896
castration - veterinary (890) 890
dose-response relationship, drug (885) 885
estrogens - pharmacology (878) 878
uterus - drug effects (852) 852
growth (843) 843
abiraterone (826) 826
prostatic neoplasms, castration-resistant - metabolism (808) 808
abiraterone acetate (789) 789
cell biology (781) 781
tumors (775) 775
kinetics (767) 767
prostatic neoplasms - metabolism (761) 761
patients (733) 733
rabbits (732) 732
tritium (728) 728
ovary (722) 722
androgen antagonists - therapeutic use (714) 714
prostatic neoplasms, castration-resistant - genetics (713) 713
urology (713) 713
disease progression (711) 711
dogs (709) 709
luteinizing hormone - metabolism (697) 697
prostate - metabolism (697) 697
increased survival (694) 694
progression (694) 694
pharmacology & pharmacy (680) 680
hormones (676) 676
apoptosis (673) 673
cancer therapies (661) 661
cattle (660) 660
biochemistry & molecular biology (651) 651
testosterone - metabolism (646) 646
prostate - drug effects (642) 642
radioimmunoassay (642) 642
sheep (640) 640
estradiol (638) 638
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (45) 45
Online Resources - Online (15) 15
Collection Dvlpm't (Acquisitions) - Vendor file (12) 12
UTL at Downsview - May be requested (7) 7
St. Michael's College (John M. Kelly) - 2nd Floor (6) 6
Media Commons - Microtexts (5) 5
Gerstein Science - Stacks (4) 4
UofT at Scarborough - Stacks (4) 4
Criminology - Stacks (3) 3
Regis College - Storage (3) 3
Thomas Fisher Rare Book - Rare Book (3) 3
UofT at Mississauga - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
East Asian (Cheng Yu Tung) - Stacks (2) 2
Music - Stacks (2) 2
OISE - Stacks (2) 2
Pontifical Inst. Mediaeval Studies - Library use only (2) 2
Institute for Christian Studies - Stacks (1) 1
Knox College (Caven) - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Scarborough - Oversize (1) 1
Victoria University CRRS - Library use only (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (31695) 31695
French (1263) 1263
German (1227) 1227
Japanese (720) 720
Russian (716) 716
Italian (396) 396
Spanish (318) 318
Portuguese (242) 242
Polish (127) 127
Chinese (76) 76
Dutch (62) 62
Czech (59) 59
Korean (51) 51
Hungarian (45) 45
Bulgarian (32) 32
Swedish (21) 21
Ukrainian (20) 20
Norwegian (14) 14
Romanian (14) 14
Serbian (13) 13
Danish (11) 11
Finnish (11) 11
Hebrew (10) 10
Croatian (8) 8
Slovak (8) 8
Turkish (6) 6
Afrikaans (4) 4
Arabic (3) 3
Latin (3) 3
Indonesian (2) 2
Persian (2) 2
Slovenian (2) 2
Greek (1) 1
Hindi (1) 1
Welsh (1) 1
Yiddish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 2017, Volume 123, Issue 18, pp. 3532 - 3539
BACKGROUND Breast cancer 2 (BRCA2)‐associated breast and ovarian cancers are sensitive to platinum‐based chemotherapy. It is unknown whether BRCA2‐associated... 
DNA damage repair | prostate cancer | castration resistance | breast cancer 2 (BRCA2) | carboplatin | SURVIVAL | MUTATION CARRIERS | GUIDELINES | OVARIAN-CANCER | DISCOVERY | IMPACT | GENOMICS | THERAPY | ONCOLOGY | FRAMEWORK | DNA-SEQUENCING DATA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Prostatic Neoplasms, Castration-Resistant - genetics | Prostatic Neoplasms, Castration-Resistant - pathology | Taxoids - therapeutic use | Neoplasm Metastasis | Carboplatin - therapeutic use | Neoplasm Invasiveness - pathology | Genes, BRCA2 | Germ-Line Mutation | Adult | Retrospective Studies | Genetic Predisposition to Disease | Prostatic Neoplasms, Castration-Resistant - drug therapy | Cancer Care Facilities | Prostate-Specific Antigen - blood | Disease-Free Survival | Survival Analysis | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Neoplasm Staging | Cohort Studies | Care and treatment | Chemotherapy | Usage | Men | Gene therapy | Prostate cancer | Health aspects | Cancer | Prostate-specific antigen | Metastasis | Taxane | Blood | Metastases | Gene sequencing | Confidence intervals | Castration | Platinum | Consultation | Deoxyribonucleic acid--DNA | BRCA2 protein | Antigens | Breast cancer | Tumor cell lines | Patients | Current carriers | Corrosion resistance | Carboplatin | Mutation | Prostate | DNA sequencing | BRCA2 | castration-resistance
Journal Article
Annals of oncology, ISSN 0923-7534, 2017, Volume 28, Issue 7, pp. 1508 - 1516
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically... 
Castration-resistant prostate cancer | Biomarker | Enzalutamide | Abiraterone | Plasma DNA | Androgen receptor | SURVIVAL | androgen receptor | abiraterone | CIRCULATING TUMOR DNA | ONCOLOGY | castration-resistant prostate cancer | MODEL | plasma DNA | biomarker | enzalutamide | Phenylthiohydantoin - adverse effects | Multivariate Analysis | Predictive Value of Tests | Prospective Studies | Circulating Tumor DNA - genetics | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Male | Prostatic Neoplasms, Castration-Resistant - genetics | Patient Selection | Antineoplastic Agents, Hormonal - adverse effects | Time Factors | DNA Mutational Analysis | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Adult | Odds Ratio | Precision Medicine | Receptors, Androgen - blood | Androstenes - adverse effects | Prostatic Neoplasms, Castration-Resistant - blood | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Androstenes - therapeutic use | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Multiplex Polymerase Chain Reaction | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Disease-Free Survival | Receptors, Androgen - genetics | Aged | Biomarkers, Tumor - genetics | Prostatic Neoplasms, Castration-Resistant - mortality | Circulating Tumor DNA - blood | Mutation | Editor's Choice | Original
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 26, pp. 2465 - 2474
Journal Article
BJU international, ISSN 1464-4096, 2017, Volume 120, Issue 5B, pp. E30 - E44
Journal Article
European urology, ISSN 0302-2838, 2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | PLACEBO | DOCETAXEL CHEMOTHERAPY | PHASE-3 | TRIAL | MITOXANTRONE PLUS PREDNISONE | THERAPY | MEN | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | LIFE | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer
Journal Article
European Urology, ISSN 0302-2838, 2013, Volume 64, Issue 1, pp. 150 - 158
Abstract Background The phosphatase and tensin homolog ( PTEN ) tumor suppressor gene is deregulated in many advanced prostate cancers, leading to activation... 
Urology | Castration-resistant prostate cancer | Biomarker | Proteomics | mTOR inhibitor | PTEN | Everolimus | Immune system | MAMMALIAN TARGET | RAPAMYCIN | CELLS | ACTIVATION | TESTOSTERONE | AKT | PTEN GENOMIC DELETION | INHIBITION | PATHWAY | UROLOGY & NEPHROLOGY | RAD001 | Prospective Studies | Prostatic Neoplasms, Castration-Resistant - enzymology | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Prostatic Neoplasms, Castration-Resistant - immunology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Prostatic Neoplasms, Castration-Resistant - pathology | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Time Factors | Antineoplastic Agents - adverse effects | T-Lymphocytes - drug effects | Kallikreins - blood | Sirolimus - adverse effects | PTEN Phosphohydrolase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Prostatic Neoplasms, Castration-Resistant - blood | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostate-Specific Antigen - blood | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | T-Lymphocytes - immunology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Chemotherapy | Angiogenesis inhibitors | Prostate cancer | Cancer | Tumors
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 15, pp. 1408 - 1418
Journal Article
Annals of oncology, ISSN 0923-7534, 2015, Volume 26, Issue 8, pp. 1589 - 1604
Journal Article
Molecular therapy, ISSN 1525-0016, 2017, Volume 25, Issue 8, pp. 1959 - 1973
Castration-resistant prostate cancer (CRPC) that occurs after the failure of androgen deprivation therapy is the leading cause of deaths in prostate cancer... 
chemo-resistance | cell cycle | PLK1 | long noncoding RNA HOXD-AS1 | WDR5 | castration-resistant prostate cancer | CRPC | AURKA | Cell Cycle - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Gene Expression Profiling | Biomarkers, Tumor | Cell Movement - genetics | Prostatic Neoplasms, Castration-Resistant - genetics | Prostatic Neoplasms, Castration-Resistant - pathology | Gene Knockdown Techniques | DNA Methylation | Neoplasm Metastasis | Neoplasm Grading | RNA Interference | Cell Transformation, Neoplastic - genetics | Prostatic Neoplasms, Castration-Resistant - therapy | Adult | Antineoplastic Agents - pharmacology | Promoter Regions, Genetic | Cell Proliferation - genetics | Histone-Lysine N-Methyltransferase - genetics | RNA, Long Noncoding - genetics | Drug Resistance, Neoplasm - genetics | Cell Line, Tumor | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Neoplasm Staging | Cell proliferation | Transcription | Polo-like kinase 1 | Laboratories | Metastasis | Kinases | Cancer therapies | Lymph nodes | Metastases | Proteins | Castration | Cell cycle | DNA methylation | Cell survival | Therapeutic applications | Grants | Gene expression | Bladder cancer | Androgens | Molecular modelling | Higher education | Lysine | Medical prognosis | Prostate cancer | Prostate | Histone H3 | Tumors | Original
Journal Article